Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Consensus: Hold — Seven brokerages average a "Hold" rating on ZNTL (1 sell, 4 hold, 1 buy, 1 strong buy) with a mean 12‑month price target of $5.83.
• Analyst views are mixed: Guggenheim upped its target to $10 and rated the stock "Buy," while Weiss and Wall Street Zen have issued "Sell" calls and Wells Fargo initiated at "Equal Weight" with a $5 target.
• Company and market snapshot: Zentalis is a clinical‑stage oncology firm (lead candidate ZN‑c3 in Phase I); shares opened at $4.23, market cap ~$301M, 52‑week range $1.13–$6.95, and it missed last quarter's EPS (‑$0.49 vs. ‑$0.41 est.).

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been given an average rating of "Hold" by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $5.8333.

Several equities research analysts have recently weighed in on the company. Guggenheim increased their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, April 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Finally, Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They set an "equal weight" rating and a $5.00 price target for the company.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. JPMorgan Chase & Co. raised its position in Zentalis Pharmaceuticals by 31.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company's stock valued at $1,092,000 after buying an additional 172,628 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Zentalis Pharmaceuticals by 35.3% during the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company's stock worth $48,000 after acquiring an additional 8,236 shares during the last quarter. Private Advisor Group LLC purchased a new position in Zentalis Pharmaceuticals during the 1st quarter worth $74,000. Ishara Investments LP bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth $1,782,000. Finally, 5AM Venture Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 705.7% in the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company's stock worth $5,330,000 after acquiring an additional 3,457,913 shares in the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $4.23 on Friday. The firm has a 50 day moving average price of $3.29 and a two-hundred day moving average price of $2.40. The stock has a market cap of $301.13 million, a P/E ratio of -2.23 and a beta of 1.99. Zentalis Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.08). Analysts predict that Zentalis Pharmaceuticals will post -1.94 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.